India Pharma Outlook Team | Friday, 23 January 2026
Corona Remedies Limited has secured the Eurasian Economic Union – Good Manufacturing Practices (EAEU–GMP) certification, marking a significant milestone in its global expansion.
Announced on January 22, 2026, this certification allows the company to enter the EAEU member countries — Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan. This expansion opens up access to a pharmaceutical market valued at approximately USD 25 billion.
The EAEU–GMP certification ensures that Corona Remedies adheres to international manufacturing standards, improving its global reputation. This certification highlights the company's ongoing commitment to quality and safety in producing pharmaceuticals, which is essential for market entry into these key regions.
The company is now positioned to serve the growing demand for essential medicines in these markets.
The certification further strengthens the company’s presence across therapeutic segments, including women’s health, cardio?diabetes, pain management, and urology. It signifies the company’s dedication to expanding its offerings globally while ensuring compliance with the stringent regulatory standards of the region.
Nirav K Mehta, CEO and Managing Director, emphasised that the certification enables the company to expand its operations, positioning Corona Remedies as a trusted pharmaceutical provider in the Eurasian region. He underscored that the company's focus on quality and international standards sets it apart in an increasingly competitive market.
Also Read: Max Institute & Intuitive Partner to Expand Robotic Surgery in India
Corona Remedies, one of Gujarat’s leading pharmaceutical manufacturers, aims to deliver medicines that meet global standards. This certification also positions the company as an integral part of the pharmaceutical sector in India’s top 30 firms based on domestic sales.
.jpg)
.jpg)
